Raffaele Giusti: Buprenorphine is Not a First-Line Mandate in Cancer Pain
Raffaele Giusti, European Expert at European Medicines Agency, shared JAMA Oncology’s post on X:
“Buprenorphine is not a first-line mandate in cancer pain. No comparative superiority over full µ-agonists; oncology guidance and WHO/EML keep morphine central. Policy should follow evidence – run pragmatic head-to-head trials now.”
Quoting JAMA Oncology’s post about a recent paper by Amy A. Case et al.:
“Viewpoint: As palliative care clinicians, we urge the adoption of buprenorphine as a first-line opioid for cancer pain due to its effectiveness and safety profile.”
Title: Buprenorphine for Cancer Pain—The Safest Opioid, and Patients With Cancer Cannot Get It
Authors: Amy A. Case, Mellar P. Davis, Marcin Chwistek, Ali J. Zarrabi
More posts featuring Raffaele Giusti.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023